雷莫西尤单抗联合帕博利珠单抗一线治疗晚期初治NSCLC的1期扩展队列
该1a/b期多中心开放标签试验的E队列报告了雷莫西尤单抗联合帕博利珠单抗一线治疗PD-L1阳性(TPS≥1%)晚期初治NSCLC的数据。26例患者中客观缓解率为42.3%,PD-L1 TPS≥50%者为56.3%,TPS 1%-49%者为22.2%;中位无进展生存期9.3个月,≥3级治疗相关不良事件发生率为42.3%。
要点
- PD-L1 TPS≥50%患者客观缓解率56.3%,TPS 1%-49%者为22.2%。
- 总体中位无进展生存期9.3个月,TPS≥50%者未达到,TPS 1%-49%者为4.2个月。
- ≥3级治疗相关不良事件发生率42.3%,最常见为高血压(15.4%)。
核心结论
- 雷莫西尤单抗联合帕博利珠单抗一线治疗晚期NSCLC安全性可控,疗效信号在PD-L1高表达肿瘤中最强。
研究设计与样本
- 多中心、开放标签1a/b期试验(NCT02443324)的E扩展队列,纳入26例PD-L1阳性(TPS≥1%)晚期初治NSCLC患者。
- 患者接受雷莫西尤单抗10 mg/kg联合帕博利珠单抗200 mg,每21天一次,最多35个周期。
- 探索性NanoString生物标志物分析包括三种T细胞特征(T细胞炎症、Gajewski和效应T细胞)及CD274基因表达。
主要发现
- 任何级别治疗相关不良事件发生于22例(84.6%),≥3级发生于11例(42.3%),最常见为高血压(4例,15.4%)。
- 总治疗人群客观缓解率42.3%,PD-L1 TPS≥50%者为56.3%,TPS 1%-49%者为22.2%。
- 总治疗人群中位无进展生存期9.3个月,12个月和18个月无进展生存率均为45%。
- PD-L1 TPS≥50%者中位无进展生存期未达到,TPS 1%-49%者为4.2个月。
- 总治疗人群中位总生存期未达到,12个月和18个月总生存率分别为73%和64%。
关键数值与推荐
- PD-L1阳性定义为肿瘤比例评分(TPS)≥1%。
- 雷莫西尤单抗剂量为10 mg/kg,帕博利珠单抗为200 mg,每21天一次,最多35个周期。
临床怎么用
- 该联合方案可作为PD-L1阳性晚期初治NSCLC的潜在一线选择,尤其PD-L1高表达(TPS≥50%)患者疗效信号更强。
- 治疗期间需关注高血压等不良事件,≥3级治疗相关不良事件发生率为42.3%。
局限性
- 为1期扩展队列,样本量小(26例),结果需更大规模研究验证。
- 生物标志物分析为探索性,尚未确立预测标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). METHODS: In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21 days for up to 35 cycles. PD-L1 positivity was defined as tumor proportion score (TPS) greater than or equal to 1%. Exploratory NanoString biomarker analyses included three T-cell signatures (T-cell-inflamed, Gajewski, and effector T cells) and CD274 gene expression. RESULTS: Cohort E included 26 patients. Treatment-related adverse events of any grade occurred in 22 patients (84.6%). Treatment-related adverse events of grade greater than or equal to 3 were reported in 11 patients (42.3%); the most frequent was hypertension (n = 4, 15.4%). Objective response rate was 42.3% in the treated population and 56.3% and 22.2% for patients with high (TPS ≥ 50%) and lower levels (TPS 1%-49%) of PD-L1 expression, respectively. Median progression-free survival (PFS) in the treated population was 9.3 months, and 12-month and 18-month PFS rates were 45% each. Median PFS was not reached in patients with PD-L1 TPS greater than or equal to 50% and was 4.2 months in patients with PD-L1 TPS 1% to 49%. Median overall survival was not reached in the treated population, and 12-month and 18-month overall survival rates were 73% and 64%, respectively. Biomarker data suggested a positive association among clinical response, three T-cell signatures, CD274 gene expression, and PD-L1 immunohistochemistry. CONCLUSIONS: First-line therapy with ramucirumab plus pembrolizumab has a manageable safety profile in patients with NSCLC, and the efficacy signal seems to be strongest in tumors with high PD-L1 expression.
引用
- Herbst RS, Arkenau HT, Bendell J, et al. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. J Thorac Oncol. 2020. PMID: 33068794. doi:10.1016/j.jtho.2020.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。